Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAngle Regulatory News (AGL)

  • There is currently no data for AGL

Geomerics Fundraising

5 Jul 2007 07:01

Angle PLC05 July 2007 For immediate release 5 July 2007 ANGLE plc Geomerics fundraising ANGLE plc ('ANGLE') is pleased to announce that one of its eight Progeny(R)portfolio companies, Geomerics Ltd, ('Geomerics') has secured investment of £2.0million from Trinity Hall, Cambridge ('Trinity Hall'). The transaction delivers a profit to ANGLE from fair value gain on its holdingin Geomerics of £4.0 million, which represents a return to date of 3.6x on itsinvestment in Geomerics. This illustrates the inherent value in ANGLE'sexisting portfolio companies, which it aims to realise going forward. Under the terms of the agreement, Trinity Hall is investing £2.0 million for24.0% of the issued share capital of Geomerics' enlarged share capital. Postthe transaction, ANGLE will retain a 47.9% share in the issued share capital. ANGLE founded Geomerics in 2005 to commercialise technology developed by theUniversity of Cambridge's Astrophysics Department. With the assistance ofANGLE's proven management capabilities, Geomerics has developed world-leadingtechnology applications for the computer games industry. Its first commercialproduct, Enlighten, delivers dramatically improved lighting effect capabilitiesfor computer game programmers. Rapid computation of light reflection and refraction in computer animation is akey factor in creation of greater realism in computer games. The computergaming market is forecast to grow at an average 11.4% compound annual rate to$46.5bn by 2010, with strong demand anticipated from Asia Pacific and EMEAregions. Following successful demonstrations at the Games Developer Conference, Geomericshas been invited to join both Microsoft's X-Box 360 Tools program and Sony'sPlay Station 3 tools and middleware programme. Work is currently in progress onthe Software Developer's Kit ('SDK'), which will enable a broad range ofsoftware games publishers to utilise Enlighten's enhanced capabilities in theircomputer games. Andrew Newland, Chief Executive of ANGLE plc said: "Following the recruitment of an industry leading Chief Executive, Gary Lewis,the investment from Trinity Hall represents another major step forward forGeomerics. The Company has a unique patent protected technology platform, whichwe are confident has the potential to revolutionise the growing computer gamesmarket. This deal demonstrates ANGLE's core competencies of commercialisingintellectual property and realising the hidden value in its venture portfoliocompanies." Gary Lewis, Chief Executive of Geomerics Ltd said: "We are delighted with this investment. This gives us precisely what we need toprosecute our immediate business plan and our long-term strategy. We havealready demonstrated the enormous potential of the company and our core IP withour first product 'Enlighten'. This investment will allow us to deliver thefuture products that will continue to revolutionise the games and otherindustries. The next few years are going to be extremely exciting for Geomerics." Paul ffolkes Davis, Bursar of Trinity Hall, Cambridge said: "Trinity Hall is interested in supporting early-stage science-based companies inCambridge, particularly where innovative technology has been developed withinthe University and/or its own Fellowship. The College has been impressed byGeomerics business plan and prospects to the extent of making a largerpercentage investment in it than is typical within its modest Private Equity/Venture Capital portfolio. We are pleased to be partnering ANGLE and theacademic founders in providing resources to help this exciting young companyrealise its potential. For further information: ANGLE plc 01483 295830Andrew Newland, Chief Executive Geomerics Ltd 01223 370030Gary Lewis, Chief Executive Trinity Hall, Cambridge 01223 332531Paul ffolkes Davis, Bursar Buchanan Communications 020 7466 5000Richard Darby, Suzanne Brocks, James Strong Notes to Editors ANGLE Founded in 1994, ANGLE is an international ventures and management servicescompany focusing on the commercialisation of technology and the development oftechnology-based industry. ANGLE creates, develops and advises technologybusinesses on its own behalf and for its clients. ANGLE is listed on AIM (AGL.L)and operates from offices in the UK, the US and the Middle East. Furtherinformation can be found on www.ANGLEplc.com Geomerics Ltd Geomerics Ltd was founded in 2005 by ANGLE and developed under ANGLE's Progeny(R) programme. It is one of eight such companies in the ANGLE portfolio atpresent. Geomerics is an innovation-led company specialising in graphicssoftware for the games industry and beyond. It is built on a combination ofadvanced in-house IP, a remarkable research team, and strong managementexperience. The company's first product is Enlighten. Enlighten radicallytransforms the way that lighting is handled in computer games. Instead ofpre-baking the effects of global illumination into the scene they can now becomputed at run time, allowing for fully dynamic lighting. This dramaticallyenhances realism as well as opening up a new world of creative possibilities fordesigners and artists. Further information can be found on www.geomerics.com Trinity Hall, Cambridge Trinity Hall is one of Cambridge University's oldest colleges. Private Equity/Venture Capital constitute 'alternative' asset classes in which selectiveinvestments are made. They form a small, but significant, part of the College'soverall endowment portfolio. Further information can be found on www.trinhall.cam.ac.uk This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
29th Oct 20257:00 amRNS-RCHANGE OF NAME
16th Oct 20257:00 amRNSAppointments: Interim CEO and senior board advisor
8th Oct 20257:00 amRNSStrategy Update
29th Sep 20257:00 amRNS-RPresentation of Data on Glioblastoma
12th Sep 20257:00 amRNSBoard Changes
9th Sep 20257:01 amRNSInterim Results
9th Sep 20257:00 amRNSChange of Adviser
5th Sep 20252:58 pmRNSNotice of Results
20th Aug 20257:00 amRNSANGLE announces collaboration with Myriad Genetics
8th Jul 20257:00 amRNS-RPARSORTIX ENABLES STUDY OF CANCER PROGRESSION
30th Jun 20255:50 pmRNSResult of 2025 Annual General Meeting
17th Jun 20257:00 amRNS-REACR 2025: Innovation in AR expression profiling
17th Jun 20257:00 amRNS-REACR 2025: Data demonstrating DNA dual analysis
10th Jun 20257:00 amRNS-RNovel discoveries into the biology of cancer
9th Jun 20257:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
6th Jun 20257:00 amRNSBoard Changes
28th May 20257:00 amRNSPreliminary Results
23rd May 20257:00 amRNSNotice of Results
28th Apr 20257:00 amRNS-RRESULTS SUPPORTING ANGLE’S HER2 ASSAY PROGRAMME
21st Mar 20257:00 amRNSIssue of LTIP Options and Share Options
21st Mar 20257:00 amRNSResults of Eisai Phase 2 pilot study
6th Feb 20257:00 amRNS-RNovel findings using Parsortix
29th Jan 20257:00 amRNSAnalysis of CTC-DNA and ctDNA using Illumina assay
24th Jan 202510:05 amRNS-RParsortix used in research paper from ETH Zurich
23rd Jan 20257:00 amRNSTrading Update
26th Sep 20247:00 amRNSHalf-year Report
23rd Sep 20247:00 amRNSExclusive agreement for DNA NGS panel
17th Sep 20247:00 amRNSNotice of Interim Results and Webcast
18th Jul 202410:08 amRNSStandard form for notification of major holdings
12th Jul 20243:38 pmRNSStandard form for notification of major holdings
11th Jul 20243:07 pmRNSResult of 2024 Annual General Meeting
21st Jun 20247:00 amRNSResult of open offer
18th Jun 20242:41 pmRNSPosting of 2023 Annual Report & Notice of the AGM
11th Jun 20247:00 amRNSParsortix and assays being showcased at EACR 2024
6th Jun 20244:37 pmRNSPublication of Circular
5th Jun 20244:04 pmRNSResults of placing and subscription
5th Jun 20247:00 amRNSProposed Placing, Subscription and Open Offer
5th Jun 20247:00 amRNSPreliminary Results
16th May 20247:00 amRNSStudy of ovarian cancer CTCs using Parsortix
3rd May 20247:00 amRNSNew commercial agreement with large pharma
24th Apr 20247:00 amRNSNew commercial agreement with AstraZeneca
22nd Apr 20247:00 amRNSUS and EU patents for innovative CellKeep™ slide
8th Apr 20247:00 amRNSParsortix HER2 assay showcased at AACR 2024
22nd Mar 20247:00 amRNSParsortix at European breast cancer conference
22nd Jan 20247:00 amRNSPotential utility in precision oncology
10th Jan 202412:57 pmRNSStandard form for notification of major holdings
4th Jan 20247:00 amRNSBreakthrough clinical results
2nd Jan 20247:00 amRNSContract announcement with Eisai Inc.
11th Dec 20237:00 amRNSBroker Announcement
11th Dec 20237:00 amRNSParsortix unlocks opportunities for drug discovery

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.